Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit.

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair ...

Innate Pharma has claimed long-term data from a phase 2 study show that its anti-KIR3DL2 antibody has a “sustained effect” ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and ...

When mice implanted with metastasis-prone human cancer cells were treated with compounds that targeted ACBP’s activity, none ...

Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...